Vanke A, the real estate leader's annual sales will hit a record high, the sales growth rate in the first three quarters led the TOP3, the performance certainty in the next 2-3 years is strong, the industry's survival of the fittest leading advantage is becoming more prominent, the sector and the company's valuation have room for further improvement, blocking analysts to raise the target price and profit expectations, the target price is 45% of the current price The company's financial situation is excellent, the operating income has steadily increased in the past three years, and the net profit in the past three years has increased slightly. In addition, the company's profitability is strong, and the control of bribery costs is high. The current PE is 5.8, which is in the historically low valuation range, which is lower than the valuation of other companies.
The recent average cost of Vanke A is 20.16 yuan, and the stock price is running above the cost. In the bearish market, it is currently in the rebound stage, investment
You can pay due attention. A mid-line buy signal has been found. The company is operating well, and most institutions believe that the stock is worth a long-term investment
Higher, investors can pay more attention.
Technically, the MACD appears to be underwater, and the RSI upward movement into the buy zone overall shows signs of improvement in the technical aspect.
Watson Bio cooperated with Suzhou Aibo to develop an mRNA new crown vaccine, and at the same time, the company's financial situation was normal, and its operating income experienced explosive growth in the past three years, and the decline in net profit in the third quarter contracted. However, the company's operating income growth slowed down in the third quarter. The current PE is 93.7, which is in the historical normal valuation range, which is higher than the valuation of other companies in the same industry.
The recent average cost of Watson Bio is 53.01 yuan, and the stock price is running below the cost. In the bearish market, it is currently in the rebound stage, and investors can pay due attention. The company is in good operating condition, and most institutions believe that the long-term investment value of the stock is relatively high, and investors can strengthen the barrier
concentrate.
Technically, the long upper shadow line is pulled out, the short-term moving average is combined with the bearish arrangement, and the KD J is close to the oversold area, and overall there is a risk in the technical side.
Guizhou Moutai update: This year's "national liquor" firmly sits on the industry leader, last year's performance exceeded the guidelines, the 14th Five-Year Plan "three doubles" space is still large, 21 years of volume and price rise to help accelerate the growth of performance, long-term logic is clear, is still the preferred leader, the head of the brokerage firmly optimistic about the core asset value of the company's excellent business status, the past three years of operating income and net profit have steadily improved. In addition, the company's profitability is excellent, ranking at the leading level of its peers. The current PE is 44.0, which is in the historical normal valuation range, which is moderate compared to other companies in the same industry.
The recent average cost of Kweichow Moutai is 1760.23 yuan, and the stock price is running above the cost. In the bearish market, the current rebound trend has slowed down, and investors can pay due attention. The company is in good operating condition, and most institutions believe that the long-term investment value of the stock is relatively high, and investors can add
Keep an eye out.
Technically, the short-term moving average is combined with the bearish arrangement, the KDJ indicator is in a bearish arrangement and has been in a downward trend for many consecutive days, and the overall technical side is not good.